ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy. In this interview, Michael Wang, MD, comments on ...
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. The TACTOPS trial, which ...
Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma ...
- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites - - New trial to ...
A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. The TACTOPS trial, which ...
Hosted on MSN
Autologous T cell therapy targeting multiple antigens shows promise in treating pancreatic cancer
A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. Subscribe to our newsletter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results